Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRETOX
NCT07220382Phase 4Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ventral hernia comparing OnabotulinumtoxinA Group with Placebo Group (2 arms). Primary endpoint: Primary Fascial Closure. Started Nov 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
ventral hernia
Beyond the preview
Go deeper on NCT07220382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220382.